Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um Estudo de Fase III do HMPL-760 em Combinação com R-GemOx Versus Placebo em Combinação com R-GemOx em DLBCL Recorrente/Refratório

9 de novembro de 2026 atualizado por: Hutchmed

Um Estudo Randomizado de Fase III, Duplamente Cego, Controlado Positivo para Avaliar a Eficácia, Segurança e Farmacocinética de HMPL-760 em Combinação com R-GemOx Versus Placebo em Combinação com R-GemOx em Doentes com Linfoma Difuso de Grandes Células B (DLBCL) Recorrente/Refratário

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

The target population of this study includes patients with DLBCL who are relapsed or refractory.

Tipo de estudo

Intervencional

Inscrição (Estimado)

240

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Baoding, China
        • Recrutamento
        • Baoding NO.1 Central Hospital
        • Contato:
        • Investigador principal:
          • Haiying Yao
      • Beijing, China
        • Recrutamento
        • Beijing GoBroad Hospital
        • Investigador principal:
          • Kai Hu
        • Contato:
      • Beijing, China
        • Recrutamento
        • BEIJING TONGREN HOSPITAL, Capital Medical University
        • Investigador principal:
          • Liang Wang
        • Contato:
      • Bengbu, China
        • Recrutamento
        • The First Affiliated Hospital of Bengbu Medical College
        • Contato:
        • Investigador principal:
          • Yanli Yang
      • Changchun, China
        • Recrutamento
        • The First Hospital of Jilin University
        • Investigador principal:
          • Ou Bai
        • Contato:
      • Changsha, China
        • Recrutamento
        • Hunan Cancer Hospital
        • Investigador principal:
          • Hui Zhou
        • Contato:
      • Changsha, China
        • Recrutamento
        • The Second Xiangya Hospital of Central South University
        • Investigador principal:
          • Hongling Peng
        • Contato:
      • Changsha, China
        • Recrutamento
        • People's Hospital of Hunan Province
        • Contato:
        • Investigador principal:
          • Can Liu
      • Chengdu, China
        • Recrutamento
        • West China Hospital of Sichuan University
        • Investigador principal:
          • Liqun Zou
        • Contato:
      • Chengdu, China
        • Recrutamento
        • Sichuan Provincial People's Hospital
        • Contato:
        • Investigador principal:
          • Xiaobing Huang
      • Chongqing, China
        • Recrutamento
        • The First Affiliated Hospital of Chongqing Medical University
        • Investigador principal:
          • Xin Wang
        • Contato:
      • Chongqing, China
        • Recrutamento
        • Chongqing University Cancer Hospital
        • Investigador principal:
          • Yao Liu
        • Contato:
      • Fujian, China
        • Recrutamento
        • Quanzhou First Hospital.Fujian
        • Contato:
        • Investigador principal:
          • Xiongpeng Zhu
      • Fuzhou, China
        • Recrutamento
        • Fujian Medical University Union Hospital
        • Investigador principal:
          • Jianzhen Shen
        • Contato:
      • Guangzhou, China
        • Recrutamento
        • Sun Yat-sen University Cancer Center
        • Investigador principal:
          • Zhiming Li
        • Contato:
      • Guangzhou, China
        • Recrutamento
        • Guangdong Provincial People's Hospital
        • Contato:
        • Investigador principal:
          • Xiaojuan Wei
      • Guangzhou, China
        • Recrutamento
        • ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
        • Investigador principal:
          • Yuhua Li
        • Contato:
      • Guiyang, China
        • Recrutamento
        • The Affiliated Hospital of Guizhou Medical University
        • Investigador principal:
          • Yan Zhang
        • Contato:
      • Hangzhou, China
        • Recrutamento
        • Zhejiang Cancer Hospital
        • Investigador principal:
          • Haiyan Yang
        • Contato:
      • Hangzhou, China
        • Recrutamento
        • The First Affiliated Hospital, Zhejiang University
        • Investigador principal:
          • Zhen Cai
        • Contato:
      • Harbin, China
        • Recrutamento
        • Harbin Medical University Cancer Hospital
        • Contato:
        • Investigador principal:
          • Qingyuan Zhang
      • Hefei, China
        • Recrutamento
        • The Second Affiliated Hospital of Anhui Medical University
        • Contato:
        • Investigador principal:
          • Zhimin Zhai
      • Jinan, China
        • Recrutamento
        • Qilu Hospital of Shandong University
        • Contato:
        • Investigador principal:
          • Shuqian Xu
      • Jinan, China
        • Recrutamento
        • Shandong Cancer Hospital & Institute
        • Investigador principal:
          • Zengjun Li
        • Contato:
      • Kunming, China
        • Ainda não está recrutando
        • The First Affiliated Hospital of Kunming Medical University
        • Contato:
        • Investigador principal:
          • Mingxia Shi
      • Nanchang, China
        • Recrutamento
        • Jiangxi Cancer Hospital
        • Investigador principal:
          • Yan Huang
        • Contato:
      • Nanjing, China
        • Recrutamento
        • Jiangsu Cancer Hospital
        • Investigador principal:
          • Yan Zhang
        • Contato:
      • Nanjing, China
        • Recrutamento
        • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
        • Contato:
        • Investigador principal:
          • Jingyan Xu
      • Nanning, China
        • Recrutamento
        • The First Affiliated Hospital of Guangxi Medical University
        • Investigador principal:
          • Zhigang Peng
        • Contato:
      • Qingdao, China
        • Recrutamento
        • The Affiliated Hospital of Qingdao University
        • Contato:
        • Investigador principal:
          • Xia Zhao
      • Shanghai, China
        • Recrutamento
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Investigador principal:
          • Weili Zhao
        • Contato:
      • Shanghai, China
        • Recrutamento
        • Tongji Hospital of Tongji University
        • Contato:
        • Investigador principal:
          • Ping Li
      • Shanghai, China
        • Ainda não está recrutando
        • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
        • Investigador principal:
          • Ligen Liu
        • Contato:
      • Shenyang, China
        • Recrutamento
        • Shengjing Hospital of China Medical University
        • Investigador principal:
          • Wei Yang
        • Contato:
      • Shenzhen, China
        • Recrutamento
        • Shenzhen people's hospital
        • Investigador principal:
          • Jihao Zhou
        • Contato:
      • Taiyuan, China
        • Recrutamento
        • Shanxi Provincial Cancer Hospital
        • Investigador principal:
          • Liping Su
        • Contato:
      • Tangshan, China
        • Recrutamento
        • North China University of Science and Technology Affiliated Hospital
        • Contato:
        • Investigador principal:
          • Zhenyu Yan
      • Tianjin, China
        • Recrutamento
        • Tianjin Medical University Cancer Institute & Hospital
        • Investigador principal:
          • Zhengzi Qian
        • Contato:
          • Zhengzi Qian
          • Número de telefone: 13702031222
          • E-mail: qzz@163.com
      • Tianjin, China
        • Recrutamento
        • Tianjin People's Hospital
        • Contato:
        • Investigador principal:
          • Xingli Zhao
      • Tianjin, China
        • Recrutamento
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
        • Investigador principal:
          • Dehui Zou
        • Contato:
      • Wenzhou, China
        • Recrutamento
        • The First Affiliated Hospital of WMU
        • Contato:
        • Investigador principal:
          • Songfu Jiang
      • Wuhan, China
        • Recrutamento
        • Hubei Cancer Hospital
        • Investigador principal:
          • Huijing Wu
        • Contato:
      • Wuhan, China
        • Recrutamento
        • Wuhan Union Hospital of China
        • Investigador principal:
          • Liling Zhang
        • Contato:
      • Xi'an, China
        • Recrutamento
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Investigador principal:
          • Pengcheng He
        • Contato:
      • Xi'an, China
        • Recrutamento
        • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
        • Investigador principal:
          • Jie Liu
        • Contato:
      • Xiamen, China
        • Ainda não está recrutando
        • The First Affiliated Hospital of Xiamen University
        • Investigador principal:
          • Bing Xu
        • Contato:
      • Xuzhou, China
        • Recrutamento
        • The Affiliated Hospital of Xuzhou Medical University
        • Contato:
        • Investigador principal:
          • Wei Sang
      • Zhengzhou, China
        • Recrutamento
        • Henan Cancer Hospital
        • Investigador principal:
          • Keshu Zhou
        • Contato:
      • Zhengzhou, China
        • Recrutamento
        • The First Affiliated Hospital of Zhengzhou University
        • Contato:
        • Investigador principal:
          • Xudong Zhang
      • Ürümqi, China
        • Recrutamento
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Investigador principal:
          • Yan Li
        • Contato:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Recrutamento
        • Fudan University Shanghai Cancer Center
        • Contato:
        • Investigador principal:
          • Fangfang Lv

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Sign the ICF and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. ECOG performance status score between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally measurable lesion;
  7. Expected survival is more than 12 weeks;

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  8. Clinically significant active infection;

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: The experimental group

Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Patients will receive HMPL-760 once daily (QD) orally.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Outros nomes:
  • Cloridrato de Gencitabina Injetável
  • Injeção de Rituximabe
  • Injeção de Oxaliplatina
Comparador de Placebo: The control group

Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Outros nomes:
  • Cloridrato de Gencitabina Injetável
  • Injeção de Rituximabe
  • Injeção de Oxaliplatina

Patients will receive HMPL-760 placebo once daily (QD) orally.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Progression-free survival (PFS)
Prazo: Up to approximately two years

Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.

Up to approximately two years
End of treatment (EOT)
Prazo: Up to approximately two years

Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).

Up to approximately two years
Systemic antitumor therapy
Prazo: Up to approximately two years

Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).

Up to approximately two years
Overall survival (OS)
Prazo: Up to approximately two years

OS is defined as the time from randomization to death due to any cause.

Up to approximately two years
systematic anti-tumor therapy
Prazo: Up to approximately two years

OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).

Up to approximately two years
Premature withdrawal from study treatment
Prazo: Up to approximately two years

OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).

Up to approximately two years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Independent review committee (IRC)-assessed PFS
Prazo: Up to approximately two years

Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

Up to approximately two years
IRC- and investigator-assessed objective response rate (ORR)
Prazo: Up to approximately two years

Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR)

Up to approximately two years
IRC- and investigator-assessed complete response rate (CRR)
Prazo: Up to approximately two years

Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR)

Up to approximately two years
IRC- and investigator-assessed duration of response (DoR)
Prazo: Up to approximately two years

For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first

Up to approximately two years
IRC- and investigator-assessed clinical benefit rate (CBR)
Prazo: Up to approximately two years

Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)

Up to approximately two years
IRC- and investigator-assessed time to response (TTR)
Prazo: Up to approximately two years

Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR)

Up to approximately two years
Safety Endpoints
Prazo: Up to approximately two years
  • Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious adverse events (TESAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 (NCI CTCAE 6.0).
  • Changes in laboratory tests, vital signs, 12-lead ECG, etc.
Up to approximately two years
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Prazo: At the end of Cycle 4 (each cycle is 21 days)]

including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

At the end of Cycle 4 (each cycle is 21 days)]

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Biomarker assessment
Prazo: Up to approximately two years

Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy.

Up to approximately two years
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Prazo: Up to approximately two years

Human metabolites of HMPL-760 when co-administered with R-GemOx

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Prazo: Up to approximately two years

maximum concentration in steady-state (Cmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Prazo: Up to approximately two years

time to maximum concentration in steady-state (Tmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Prazo: Up to approximately two years

Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Prazo: Up to approximately two years

The rate at which the drug is eliminated from the body (CL/F) (if applicable )

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Prazo: Up to approximately two years

The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable)

Up to approximately two years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Weili Zhao, Ruijin Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de março de 2026

Conclusão Primária (Estimado)

30 de abril de 2028

Conclusão do estudo (Estimado)

30 de dezembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

28 de janeiro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

6 de fevereiro de 2026

Primeira postagem (Real)

13 de fevereiro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .